Hatchtech appoints Hugh Alsop CEO
13 March, 2013Hatchtech has appointed Australian pharmaceutical industry veteran Hugh Alsop to the post of CEO as it prepares for phase III trials of head lice treatment DeOvo.
Consultation opens for code of best practice
13 March, 2013Having undergone an expert review, The Code of Best Practice for Reporting by Life Sciences Companies is open for comment.
Pharmaxis names new CEO
13 March, 2013 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) COO Gary Phillips will replace founding CEO Alan Robertson at the helm and will re-examine the company’s business model in light of its expected FDA setback.
Starpharma signs new agrochemical tie-up
13 March, 2013Starpharma (ASX:SPL) has signed a crop protection collaboration covering the use of its dendrimer nanotechnology platform technology by Makhteshim Agan.
Alchemia raises $10.2m in placement
12 March, 2013 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has raised $10.2m in an institutional placement and will seek another $2m via an SPP to help fund its Phase III trial of HA-Irinotecan in colorectal cancer.
Special BIO rate for Australian delegation
12 March, 2013Companies that sign up to be part of the Australian Pavilion at BIO 2013 will receive a discounted registration rate for this biotech convention.
Alchemia granted US patent
11 March, 2013 by Susan WilliamsonAlchemia has been granted a US patent for the use of HA-Irinotecan and its HyACT targeted chemotherapy platform.
Positive results for new multiple myeloma treatment
11 March, 2013A new treatment for multiple myeloma, developed by Patrys, shows promising results in patients.
Acrux’s underarm testosterone listed on PBS
07 March, 2013 by Dylan Bushell-EmblingAcrux’s (ASX:ACR) underarm testosterone treatment for androgen deficiency has been added to the PBS, via global licensing partner Eli Lilly.
Collaborative agreement to develop cancer therapies
07 March, 2013 by Susan WilliamsonNovogen has signed a collaborative agreement with the Ingham Institute to begin progressing its pipeline of cancer therapies.
Global biotech crop plantings increase 100-fold
07 March, 2013Last year marked an unprecedented 100-fold increase in biotech crop hectarage.
Imugene secures Japanese patent for Linguet
06 March, 2013 by Dylan Bushell-EmblingImugene (ASX:IMU) will receive a Japanese patent that will allow it to explore developing products to treat bone loss using its Linguet drug delivery platform.
Gene patent ruling appealed
06 March, 2013 by Susan WilliamsonCancer Voices Australia will appeal the Federal Court of Australia’s decision to allow genes to be patented.
Newcastle Uni teams with Proteologics on asthma R&D
06 March, 2013 by Dylan Bushell-EmblingUniversity of Newcastle and Israeli drug developer Proteologics have signed a deal covering joint development of an asthma treatment based on midline-1 inhibitors.
Alchemia completes recruitment for colorectal cancer trial
05 March, 2013 by Susan WilliamsonAlchemia (ASX:ACL) has completed enrolment of 415 patients for its Phase III trial of HA-Irinotecan in metastatic colorectal cancer.
